Search
# Popular search #
# Popular search #
Stock Code
603087.SHGan & Lee Pharmaceuticals’ Oral GZR18 Tablet Completes First Dosing in Phase I Clinical Trial
Gan & Lee Pharmaceuticals' Overseas Clinical Research on Insulin Glargine was Published in Journal Diabetes, Obesity and Metabolism
Gan & Lee Pharmaceuticals Announces Approval of Insulin Aspart Injection in Bolivia
Gan & Lee Pharmaceuticals' Dual Insulin Analog GZR101 Completes First Dosing in Phase II Clinical Trial
IDF 2023丨Debut of the Phase III Clinical Evidence in China for Rapilin30
Gan & Lee Pharmaceuticals Announces IND Clearance by the NMPA for the Oral GLP-1 Receptor Agonist (GZR18 Tablet)
To be a world-class pharmaceutical company with focus on global business development
Registered in 20 countries
Products launched in 18 countries
Clinical trials conducted in 12 countries
Registered in 20 countries
Products launched in 18 countries
Clinical trials conducted in 12 countries
This website uses cookies to give users like yourself the best possible content and experience. For more information about your choices regarding cookies, please review our Privacy Policy .
The site you are about to visit is maintained by a third party who is responsible for its content.
This link is provided on the Gan & Lee website as a service to our visitors. Gan & Lee is not responsible for the privacy policy of any third-party websites. Gan & Lee encourages visitors to read the privacy policy of every website that you may visit.